A Phase III Study of Sorafenib Alone versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Patients with Liver Cancer

Full Title

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma (RTOG 1112)


Sorafenib is a drug used to treat hepatocellular carcinoma (primary liver cancer). However, in many patients the cancer eventually continues to grow. Stereotactic body radiation therapy (SBRT) is another treatment for liver cancer. It involves the use of focused high-dose radiation generally delivered to the liver in five or fewer sessions.

In this study, researchers want to see if using both therapies together is more effective than sorafenib alone (the current standard of care) for treating inoperable liver cancer. Patients will be randomly assigned to receive sorafenib alone (a tablet which is taken by mouth) or SBRT followed by sorafenib.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have hepatocellular carcinoma that cannot be surgically removed or treated with other therapies (such as radiofrequency ablation or chemotherapy delivered directly to the liver).
  • Patients may not have had prior therapy with sorafenib or internal or external beam radiation therapy to the liver.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Christopher Crane at 646-888-5208.